Header
For Healthcare Professionals
Metalyse Logo
Metalyse Banner
METALYSE® 25 MG IS NOW AVAILABLE FOR THE THROMBOLYTIC TREATMENT OF ACUTE ISCHAEMIC STROKE WITHIN 4.5 HOURS FROM LAST KNOWN WELL AND AFTER EXCLUSION OF INTRACRANIAL HAEMORRHAGE1

Because Every
Minute Matters

Workflow benefit

Workflow benefit

Use of tenecteplase compared to alteplase in the treatment of acute ischaemic stroke (AIS) is associated with improved hospital efficiency and reduction in the utilisation of healthcare resources.2-4

Optimized use of nursing time

Tenecteplase, compared to alteplase, may increase the efficiency of the nursing staff, due to reduced preparation time of the thrombolytic and reduced patient monitoring time.*5-6

Optimized use of nursing time
Simpler patient transfer

Simpler patient transfer

With tenecteplase, patient transfer is simpler than with alteplase. Patients can be transferred immediately after receiving the IV bolus of tenecteplase, without the need for physician-supported medicalised transfer.†2

Efficiency supported by real-world evidence

In the treatment of AIS, the use of tenecteplase in real-world clinical practice led to reduced door-in-door-out (DIDO) and door-to-needle (DTN) times compared to alteplase.2
DIDO time, the time between arrival at first treating hospital and start of transfer for advanced post-IVT treatment in a secondary stroke center, was 22-minutes shorter with tenecteplase, compared to alteplase‡2. DTN time, the time between hospital arrival and IVT administration, was 6-minutes shorter with tenecteplase, compared to alteplase.§2

Efficiency supported by real-world evidence
Door-In-Door-Out (DIDO) Time

Door-In-Door-Out (DIDO) Time

Median DIDO was 113 min (IQR 83-153) for tenecteplase vs 135 min (IQR 100-177) for alteplase.‡2

Door-to-Needle (DTN) Time

Median DTN was 51 min (IQR 38-80) for tenecteplase vs 57 min (IQR 43-75) for alteplase.§2

Door-to-Needle (DTN) Time

A prospective, observational, open-label, sequential cohort registry study comparing key workflow and clinical metrics between tenecteplase- (n=234) and alteplase-treated (n=354) stroke patients. The study assessed whether tenecteplase use in routine clinical practice reduced thrombolytic workflow times with noninferior clinical outcomes. The primary workflow timing outcomes were the percent of patients treated within a target door-to-needle (DTN) time of 45 minutes and the percent of patients target door-in-door-out (DIDO) time within 90 minutes.

Footnotes
  • AIS: acute ischaemic stroke; CI: confidence interval; DIDO: door-in-door-out; DTN: door-to-needle; IQR: interquartile range; IV: intravenous; IVT: intravenous thrombolysis; OR: odds ratio
  • *
    Refers to the amount of time needed for monitoring the patient actively during administration of the thrombolytic.5-6 
  • †
    Refers to the requirement for continuous monitoring of patients receiving thrombolytic infusion during transfer by trained and experienced physician.5-6
  • ‡
    DIDO was measured as the difference in the documented times from emergency department arrival at the treating hospital to discharge from that emergency department for transfer to another hospital for a higher level of care post thrombolysis, including but not limited to assessment for mechanical thrombectomy.2
  • §
    DTN time was measured as the difference between the documented times of hospital arrival (or symptom discovery for inpatient stroke) and the thrombolytic bolus.2
References

  1. Metalyse® European Summary of Product Characteristics.

  2. Warach S.J. et al. Stroke 2022; 53:3583–3593. 

  3. Mahawish K. et al. Stroke 2021; 52:e590-e593. 

  4. Warach S.J. and Saver J.L. JAMA Neurol. 2020; 77(10):1203-1204.

  5. Menon B. K. et al. Lancet 2022; 400:161–169. 

  6. Actilyse® European Summary of Product Characteristics.